Authors: David J. Lewis, Aron Thall, Pier Luigi Zinzani, John Radford, Bo Huang, Camilla Fowst, Fiona Miall, Satjit Brar, C. Burton, Alex F. Herrera, Graham P. Collins, Armando Santoro, William Townsend
Contributors: Herrera A.F., Burton C., Radford J., Miall F., Townsend W., Santoro A., Zinzani P.L., Lewis D., Fowst C., Brar S., Huang B., Thall A., Collins G.P.
Source:
Herrera, A F, Burton, C, Radford, J, Miall, F, Townsend, W, Santoro, A, Zinzani, P L, Lewis, D, Fowst, C, Brar, S, Huang, B, Thall, A & Collins, G P 2021, ' Avelumab in relapsed/refractory classical Hodgkin lymphoma : phase 1b results from the JAVELIN Hodgkins trial ', Blood Advances, vol. 5, no. 17, pp. 3387-3396 . https://doi.org/10.1182/BLOODADVANCES.2021004511
Blood Adv
Subject Terms: Hematology, Gastroenterology, medicine.medical_specialty, medicine, Blockade, Pharmacokinetics, business.industry, business, Refractory, Monoclonal, Rash, medicine.symptom, Adverse effect, Nausea, Hematopoietic stem cell transplantation, medicine.medical_treatment, Internal medicine, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal, Humanized, Hodgkin Disease/drug therapy, Humans, Neoplasm Recurrence, Local/drug therapy, Tumor Microenvironment, Antibodies, Monoclonal, Human, Neoplasm Recurrence, Local, Hodgkin Disease, Clinical Trials and Observations
File Description: application/pdf; STAMPA
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::592fc4d3b23864aef2a200dd739b1a36
https://doi.org/10.1182/bloodadvances.2021004511
Authors: Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle
Contributors: Laboratory of Molecular and Medical Oncology, Clinical sciences, Medical Oncology, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer
Source: Journal for ImmunoTherapy of Cancer, Vol. 10, no.5, p. e004076 (2022)
Subject Terms: Clinical Trials as Topic, Drug Therapy, Combination, Immunotherapy, Macrophages, T-Lymphocytes, Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung/drug therapy, Fatigue/chemically induced, Humans, immune checkpoint inhibitors, Ligands, Lung Neoplasms/drug therapy, Melanoma/drug therapy, Receptor Protein-Tyrosine Kinases, Urinary Bladder Neoplasms/drug therapy
File Description: application/pdf
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2c2dc4accf632390ea464a967fc522a
http://hdl.handle.net/10230/54798
Authors: Guy Gorochov, Delphine Sterlin
Contributors: Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), D.S. was supported for this work by an Institut Pasteur/Assistance Publique – Hôpitaux de Paris (APHP) interface fellowship. The Gorochov Laboratory is financed by Inserm, APHP (PHRC-20-0375), Sorbonne Université (SARS-CoV-2 Program), Région Île de France Domaines d’Intérêt Majeur (DIM Thérapie Génique), Fondation de France, and Agence Nationale de la Recherche (iCOVID ANR-20-COVI-0025)., Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI)
Source:
Pharmacology
Pharmacology, Karger, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Pharmacology, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Subject Terms: Immunoglobulin A, Therapeutic antibody, Bioengineering, Primary antibody deficiency, MESH: Animals, MESH: Anti-Inflammatory Agents / therapeutic use, MESH: Host-Pathogen Interactions, MESH: Humans, MESH: Immunoglobulin A / adverse effects, MESH: Immunoglobulin A / therapeutic use, MESH: Immunotherapy* / adverse effects, MESH: Inflammation / drug therapy, MESH: Inflammation / immunology, MESH: Mice, MESH: Neoplasms / drug therapy, MESH: Neoplasms / immunology, MESH: Antibodies, Monoclonal / adverse effects, MESH: SARS-CoV-2 / immunology, MESH: Antibodies, Monoclonal / therapeutic use, MESH: Antineoplastic Agents, Immunological / therapeutic use, MESH: Antiviral Agents / adverse effects, MESH: Antiviral Agents / therapeutic use, MESH: COVID-19 / drug therapy, MESH: COVID-19 / immunology, MESH: COVID-19 / virology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Pharmacology, General Medicine, Immunotherapy, medicine.medical_treatment, medicine, Rotavirus, medicine.disease_cause, Virus, Poliovirus, Antibody, biology.protein, biology, Gut flora, biology.organism_classification, Immune system, Immunology, business.industry, business
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9a12b1182e8d150ab11b2aa001c856
https://hal.sorbonne-universite.fr/hal-03139698
Authors: Torben Plesner, Howard Yeh, Jacob P. Laubach, Mary E. Guckert, Paul G. Richardson, Ulrik Lassen, Antonio Palumbo, Pamela L. Clemens, Carla de Boer, Hendrik-Tobias Arkenau, Linda Basse, A. Kate Sasser, Monique C. Minnema, Steen Lisby, Charlotte Lemech, Jakub Krejcik, Jianping Wang, Nushmia Z. Khokhar, Henk M. Lokhorst, Tahamtan Ahmadi, Peter Gimsing
Contributors: Hematology, CCA - Clinical Therapy Development
Source:
Blood, 128(14), 1821-1828. American Society of Hematology
Blood, 128(14), 1821. American Society of Hematology
Plesner, T, Arkenau, H-T, Gimsing, P, Krejcik, J, Lemech, C, Minnema, M C, Lassen, U, Laubach, J P, Palumbo, A, Lisby, S, Basse, L, Wang, J, Sasser, A K, Guckert, M E, de Boer, C, Khokhar, N Z, Yeh, H, Clemens, P L, Ahmadi, T, Lokhorst, H M & Richardson, P G 2016, ' Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma ', Blood, vol. 128, no. 14, pp. 1821-1828 . https://doi.org/10.1182/blood-2016-07-726729
Subject Terms: Clinical Trials and Observations, Journal Article, Cell Biology, Hematology, Immunology, Biochemistry, Refractory, Medicine, business.industry, business, Autologous stem-cell transplantation, Dexamethasone, medicine.drug, Multiple myeloma, medicine.disease, Daratumumab, Lenalidomide, Gastroenterology, medicine.medical_specialty, Pharmacology, Thalidomide, Neutropenia, Internal medicine, Aged, Antibodies, Monoclonal/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Demography, Dexamethasone/adverse effects, Disease-Free Survival, Female, Humans, Middle Aged, Multiple Myeloma/drug therapy, Recurrence, Thalidomide/adverse effects, Treatment Outcome
File Description: image/pdf
Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4af588d173f91d363cd957f3c2d392ad
Authors: Serge Ferrari, Sylvie Ferrari-Lacraz
Source: Osteoporosis International, Vol. 22, No 2 (2011) pp. 435-46
Subject Terms: musculoskeletal diseases, ddc:618.97, Animals, Antibodies, Monoclonal/adverse effects/pharmacology, Arthritis, Rheumatoid/physiopathology, B-Lymphocytes/metabolism, Bone Resorption/physiopathology, Female, Humans, Infection/chemically induced, Mice, Neoplasms/chemically induced, Osteoblasts/metabolism, Osteoclasts/metabolism, Osteoporosis/physiopathology, Osteoprotegerin/pharmacology, RANK Ligand/adverse effects/pharmacology, Rats, Receptor Activator of Nuclear Factor-kappa B/antagonists & inhibitors, T-Lymphocytes/metabolism, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Endocrinology, Diabetes and Metabolism, Denosumab, medicine.drug, medicine, Antibody, biology.protein, biology, RANKL, Arthritis, medicine.disease, Immunology, Osteoclast, medicine.anatomical_structure, Immune system, business.industry, business, Inflammation, medicine.symptom, Osteoprotegerin
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93590c4b9c41bd23603b324ca0f98b02
http://doc.rero.ch/record/317114/files/198_2010_Article_1326.pdf
Authors: Jean-Charles Soria, Sylvie Rusakiewicz, Sophie Postel-Vinay, Aurélien Marabelle, Laurence Zitvogel, Sandrine Aspeslagh
Contributors: Medical Oncology
Subject Terms: Animals, Antibodies, Monoclonal/adverse effects, Humans, Immunotherapy/adverse effects, Neoplasms/drug therapy, Receptors, OX40/antagonists & inhibitors, Signal Transduction/drug effects, Treatment Outcome, TUMOR MICROENVIRONMENT, Cancer Research, Oncology, Monoclonal antibody, medicine.drug_class, medicine, CD134, Tumor microenvironment, Cancer immunotherapy, medicine.medical_treatment, Immune system, Immunoglobulin superfamily, Immunology, Immunotherapy, Biology, Immune checkpoint
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d26d285016f923a2aaf9eff61c8517c7
https://biblio.vub.ac.be/vubir/rationale-for-antiox40-cancer-immunotherapy(96b6cd9e-4cdb-46f5-8fc4-1eb4dee8b3ce).html
Authors: B. De Lafontan, H. Laharie-Mineur, Moïse Namer, David Azria, Yazid Belkacemi, Bruno Cutuli, Mahmut Ozsahin, Hugo Marsiglia, Joseph Gligorov, L. Aimard, Eric-Charles Antoine
Source: Annals of Oncology : Official Journal of the European Society For Medical Oncology, vol. 19, no. 6, pp. 1110-1116
Subject Terms: Oncology, Hematology, Cumulative dose, Trastuzumab, medicine.drug, medicine, business.industry, business, Internal medicine, medicine.medical_specialty, Breast cancer, medicine.disease, Surgery, Cancer, Esophagitis, Breast disease, Acute toxicity, Radiation therapy, medicine.medical_treatment, Gastroenterology, Antibodies, Monoclonal/adverse effects, Antineoplastic Agents/adverse effects, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Breast Neoplasms/therapy, Combined Modality Therapy/adverse effects, Dermatitis/etiology, Esophagitis/etiology, Radiotherapy, Adjuvant/adverse effects, Receptor, ErbB-2/metabolism
File Description: application/pdf
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86795a372b82b619622f496384aeaba0
https://doi.org/10.1093/annonc/mdn029
Authors: Sébastien Baechler, Claudine Helg, Marek Kosinski, Yves Chalandon, Angelika Bischof Delaloye, Franz Buchegger, Gilles Allenbach, Nicolas Ketterer, John O. Prior, Osman Ratib
Source: Clinical Nuclear Medicine, Vol. 37, No 10 (2012) pp. 960-964
Subject Terms: ddc:616.0757, ddc:616, Adult, Aged, Antibodies, Monoclonal/adverse effects, Female, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Kaplan-Meier Estimate, Lymphoma/radiotherapy/surgery, Male, Middle Aged, Radioimmunotherapy/adverse effects, Recurrence, Retrospective Studies, Time Factors, Transplantation, Homologous/adverse effects, surgical procedures, operative, hemic and lymphatic diseases, immune system diseases, Radiology, Nuclear Medicine and imaging, General Medicine, Bone marrow, medicine.anatomical_structure, medicine, Mantle cell lymphoma, medicine.disease, Internal medicine, medicine.medical_specialty, Toxicity, Hematopoietic stem cell transplantation, medicine.medical_treatment, Lymphoma, Follicular lymphoma, Surgery, business.industry, business, Gastroenterology, Radioimmunotherapy, Immunotherapy
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b757fa4e1916413f6c495cad4aca10c
https://archive-ouverte.unige.ch/unige:78652
Authors: Giuseppe Pantaleo, Mathieu Canales, Renaud Du Pasquier, Hans H. Hirsch, Andreas Lysandropoulos, Samantha Jilek, Laurence Guignard, Emilie Jaquiéry, Myriam Schluep
Contributors: Institut für Medizinischediagnostik, Mikrobiologie, University of Bassel, Laboratories of Neuroimmunology [Lausanne, Switzerland] (Department of Clinical Neurosciences), Lausanne University Hospital [Switzerland], Centre de Recherche Universitaire Lorrain d'Histoire (CRULH), Université de Lorraine (UL), Service of Neurology [CHUV, Lausanne, Switzerland], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital
Source:
Lancet Neurology, vol. 9, no. 3, pp. 264-272
The Lancet Neurology
The Lancet Neurology, Elsevier, 2010, 9 (3), pp.264-272. ⟨10.1016/S1474-4422(10)70006-5⟩
Subject Terms: Adult, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, CD4-Positive T-Lymphocytes/immunology, CD4-Positive T-Lymphocytes/virology, CD8-Positive T-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/virology, Cross-Sectional Studies, Female, Humans, Immunity, Cellular/immunology, JC Virus/immunology, Leukoencephalopathy, Progressive Multifocal/chemically induced, Leukoencephalopathy, Progressive Multifocal/immunology, Longitudinal Studies, Lymphocyte Activation/immunology, Male, Multiple Sclerosis/drug therapy, Multiple Sclerosis/immunology, Prospective Studies, viruses, Neurology (clinical), Oligodendrocyte, medicine.anatomical_structure, medicine, Immune system, Multiple sclerosis, medicine.disease, Progressive multifocal leukoencephalopathy, Natalizumab, medicine.drug, Virus, Immunology, JC virus, medicine.disease_cause, business.industry, business, Virology, Myelin oligodendrocyte glycoprotein, biology.protein, biology, [SHS]Humanities and Social Sciences, [SHS.HIST]Humanities and Social Sciences/History, ComputingMilieux_MISCELLANEOUS
File Description: application/pdf
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff715253ed953ce1bf2addb65d998daf
https://serval.unil.ch/notice/serval:BIB_4C0A400887F2
Source: ODYSSEY OUTCOMES Committees and Investigators , Tricoci , P , Roe , M T , Mahaffey , K W , Poulsen , S H , Raungaard , B , Clemmensen , P , Bang , L E , May , O , Bøttcher , M , Hove , J D , Frost , L , Gislason , G H , Larsen , J , Johansen , P B , Hald , F , Jeppesen , J , Nielsen , T , Kristensen , K S , Walichiewicz , P M , Lomholdt , J D , Klausen , I C , Nielsen , P K , Davidsen , F , Videbaek , L , Gache , C , Badreddine , E & Bekkouche , M 2018 , ' Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome ' , The New England Journal of Medicine , vol. 379 , no. 22 , pp. 2097-2107 .
Index Terms: Acute Coronary Syndrome/blood, Adult, Aged, Antibodies, Monoclonal/adverse effects, Anticholesteremic Agents/adverse effects, Cardiovascular Diseases/epidemiology, Cholesterol, LDL/blood, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia/complications, Male, Middle Aged, Proprotein Convertase 9/antagonists & inhibitors, article
URL:
Additional Titles: Immunotherapy is cancer treatment with a novel side-effect profile
Source: Kondrup , M , Raunkilde , L , Svane , I M , Schmidt , H & Bastholt , L 2017 , ' Immunterapi er kræftbehandling med en helt ny bivirkningsprofil ' , Ugeskrift for Laeger , bind 179 , V05170365 . <
Index Terms: Antibodies, Monoclonal/adverse effects, Antineoplastic Agents, Immunological/adverse effects, CTLA-4 Antigen/antagonists & inhibitors, Chemical and Drug Induced Liver Injury/etiology, Drug-Related Side Effects and Adverse Reactions/diagnostic imaging, Endocrine System Diseases/chemically induced, Gastrointestinal Diseases/chemically induced, Humans, Immunotherapy/adverse effects, Lung Diseases/chemically induced, Mobile Applications, Neoplasms/drug therapy, Practice Guidelines as Topic, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Skin Diseases/chemically induced, Tomography, X-Ray Computed, article
URL:
Source: Donia , M , Pedersen , M & Svane , I M 2017 , ' Cancer immunotherapy in patients with preexisting autoimmune disorders ' , Seminars in Immunopathology , vol. 39 , no. 3 , pp. 333-337 .
Index Terms: Antibodies, Monoclonal/adverse effects, Antineoplastic Agents/adverse effects, Autoimmune Diseases/complications, B7-H1 Antigen/antagonists & inhibitors, CTLA-4 Antigen/antagonists & inhibitors, Humans, Immune Tolerance, Immunosuppression, Immunotherapy/adverse effects, Molecular Targeted Therapy/adverse effects, Neoplasms/complications, Neoplasms, Second Primary/etiology, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Risk, Treatment Outcome, article
URL:
Source: Blood, 129 (5
Index Terms: Hématologie, Acute Disease, Adult, Antibodies, Monoclonal -- adverse effects -- therapeutic use, Antilymphocyte Serum -- adverse effects -- therapeutic use, Drug Resistance, Female, Graft vs Host Disease -- drug therapy, Humans, Immunosuppressive Agents -- adverse effects -- therapeutic use, Male, Middle Aged, Proportional Hazards Models, Steroids -- therapeutic use, Survival Analysis, Treatment Outcome, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Clinical cancer research, 20 (8
Index Terms: Cancérologie, Adult, Aged, Animals, Antibodies, Monoclonal -- adverse effects -- pharmacokinetics -- therapeutic use, Area Under Curve, CHO Cells, Cricetinae, Cricetulus, Dose-Response Relationship, Drug, Fatigue -- chemically induced, Female, Humans, Interleukin-6 -- immunology, Liver -- drug effects -- physiopathology, Male, Metabolic Clearance Rate, Middle Aged, Mutation, Nausea -- chemically induced, Neoplasms -- drug therapy -- genetics -- metabolism, Neutropenia -- chemically induced, Proto-Oncogene Proteins -- genetics, Treatment Outcome, ras Proteins -- genetics, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Clinical cancer research, 20 (8
Index Terms: Cancérologie, Adult, Aged, Animals, Antibodies, Monoclonal -- adverse effects -- pharmacokinetics -- therapeutic use, Area Under Curve, CHO Cells, Cricetinae, Cricetulus, Dose-Response Relationship, Drug, Fatigue -- chemically induced, Female, Humans, Interleukin-6 -- immunology, Liver -- drug effects -- physiopathology, Male, Metabolic Clearance Rate, Middle Aged, Mutation, Nausea -- chemically induced, Neoplasms -- drug therapy -- genetics -- metabolism, Neutropenia -- chemically induced, Proto-Oncogene Proteins -- genetics, Treatment Outcome, ras Proteins -- genetics, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Journal of immunotherapy, 36 (3
Index Terms: Anatomopathologie, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal -- adverse effects -- therapeutic use, Antineoplastic Agents -- adverse effects -- therapeutic use, C-Reactive Protein -- analysis, CTLA-4 Antigen -- immunology, Female, Humans, Lymphocyte Count, Male, Melanoma -- drug therapy -- immunology, Middle Aged, Treatment Outcome, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Journal of immunotherapy, 36 (3
Index Terms: Anatomopathologie, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal -- adverse effects -- therapeutic use, Antineoplastic Agents -- adverse effects -- therapeutic use, C-Reactive Protein -- analysis, CTLA-4 Antigen -- immunology, Female, Humans, Lymphocyte Count, Male, Melanoma -- drug therapy -- immunology, Middle Aged, Treatment Outcome, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: The Lancet Oncology, Vol. 12, no. 4, p. 333-343 (2011)
Index Terms: Adult, Aged, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local - drug therapy, mortality, Neoplasms, Squamous Cell - drug therapy, mortality, Organoplatinum Compounds - therapeutic use, Receptor, Epidermal Growth Factor - antagonists & inhibitors, Salvage Therapy, Treatment Failure, Aged, 80 and over, Antibodies, Monoclonal - adverse effects, therapeutic use, Carcinoma - drug therapy, mortality, Disease-Free Survival, Female, Head and Neck Neoplasms - drug therapy, mortality, Humans, Male, info:eu-repo/semantics/article
Source: European journal of heart failure, 13 (1
Index Terms: Cancérologie, Anthracyclines -- adverse effects -- therapeutic use, Antibodies, Monoclonal -- adverse effects -- therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents -- adverse effects -- therapeutic use, Cardiology -- standards, Cardiotoxins, Cardiovascular System -- drug effects, Education, Europe, Heart Failure -- chemically induced, Humans, Neoplasms -- drug therapy, Practice Guidelines as Topic, Receptor, Epidermal Growth Factor -- drug effects, Risk Factors, Sirolimus -- antagonists & inhibitors, Anthracyclines, Cardio-oncology, Cardiotoxicity, Consensus statement, Heart failure, Targeted therapy, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Clinical Cancer Research, Vol. 17, no. 10, p. 3469-3477 (2011)
Index Terms: Adult, Aged, Disease Progression, Female, Gene Expression Regulation, Neoplastic - drug effects, radiation effects, Humans, Male, Middle Aged, Neoadjuvant Therapy, Rectal Neoplasms - drug therapy, genetics, pathology, radiotherapy, Retrospective Studies, Tumor Markers, Biological - analysis, genetics, Aged, 80 and over, Antibodies, Monoclonal - adverse effects, therapeutic use, Antineoplastic Agents - adverse effects, therapeutic use, Biomarkers, Pharmacological - analysis, metabolism, Carcinoma - drug therapy, genetics, pathology, radiotherapy, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Combined Modality Therapy, info:eu-repo/semantics/article